We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
- Authors
Yale, J-F; Bakris, G; Cariou, B; Yue, D; David-Neto, E; Xi, L; Figueroa, K; Wajs, E; Usiskin, K; Meininger, G
- Abstract
Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m(2)].
- Publication
Diabetes, obesity & metabolism, 2013, Vol 15, Issue 5, p463
- ISSN
1463-1326
- Publication type
Journal Article
- DOI
10.1111/dom.12090